News

In celebration of the International Clinical Trials Day, a global celebration honoring a Scottish physician James Lind, who launched the first documented clinical trial on scurvy on May 20, 1747, we set up a booth at Queen Mary Hospital this year to showcase the story behind this special occasion, and to raise social awareness on the significance of clinical trials in medical advancement!

Other than the informative posters educating the public on the close association between new drug discovery and clinical trials, we had also prepared thoughtfully-designed souvenirs to interest participants who passed by our booth! One of our Panda Ambassadors, Dr Hong also joined us at the booth to bring more smiles and energy to the event, creating a welcome space for dialogues with all the participants. We hope you have all enjoyed, and look forward to bringing more medical knowledge to you all soon!

Thank you to all the patients who participated in the oral medication study related to Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer (CTC1946) between 2020 and 2023. We have the honor to inform you that the clinical data of the Phase 3 clinical trial has been submitted to the U.S. Food and Drug Administration (FDA) and the oral medication has been approved, paving ways for new treatment targeting breast cancer.

Clinical Research Governance World Conference 2025 was successfully concluded on January 16, 2025. With over 200 on-site and 800 online registrations, the engagement from all these indsutrial experts was what make the event special. It is our honour to have Professor Lo Chung-mau, Secretary for Health of HKSAR, and Professor Max Shen, Vice-President (Research) of The University of Hong Kong, deliver the opening remarks. Their insights set the tone for a productive conference.

We hope to see you all in the our future events again!

We are delighted to welcome a group of secondary school students visiting our HKU Phase 1 Clinical Trials Centre on November 22, 2024. It was an excellent opportunity to enlighten the next generation about the vital role of clinical trials in progressing public health.

The information session also included introduction to the diversified research projects that our Centre has been working on, sparking their interests in the clinical trials industry and research outputs that can benefit the community.

Study Intervention:

Any drug, medical device, medical method, or procedure aimed at treating, alleviating, diagnosing, or preventing diseases or medical conditions.

Adverse Event (AE):

An adverse condition that volunteers encounter during the research process (e.g., discomfort, symptoms of illness), regardless of whether the adverse event was expected or related to the research procedure or products. The research team must document, analyze, and follow up on each adverse event in detail.

The University of Hong Kong (HKU) welcomes the HKSAR Government's announcement today (23 September) on designating its LKS Faculty of Medicine (HKUMed) as the operator of the Greater Bay Area International Clinical Trial Institute (the GBAICTI). Located in the Hong Kong Park of the Hetao Shenzhen–Hong Kong Science and Technology Innovation Co-operation Zone, the GBAICTI is scheduled to begin operations in the fourth quarter of this year, with the aim of becoming an innovative clinical research platform with global influence to attract mainland and multinational pharmaceutical institutions.

Available in Chinese only.

On August 1, 2024, 20 secondary students visited the HKU Phase 1 Clinical Trials as a part of the HKUMedify – Clinical Exposure Programme 2024. Through our introduction of the realistic clinical trials procedure, in-depth tour of the Phase 1 Centre, and their hands-on experience on simulating volunteer recruitment, we believe the session offers remarkable exposure on the importance of volunteer protection, scientific validity and data integrity.

The major difference between phase 1 clinical study and the later phases of clinical study is that its participants are usually healthy volunteers. Do you know the end-to-end procedure of preparing for a phase 1 study, and the steps that volunteers have to go through?

The video below will guide you through the journey of phase 1 clinical study, introducing you to all the details of this specific phase!

When you enrol in clinical trials, have you ever thought of why you might not be selected in some of them? Are you clear about the eligibility criteria of clinical trials? Read more about the eligibility, inclusion and exclusion criteria below!

Eligibility Criteria:

It includes a series of basic, medical, testing-related inclusion and exclusion conditions (such as age, height, weight, blood pressure, pre-existing medical conditions, etc.) to determine whether volunteers are suitable for participating in the study.

Inclusion Criteria:

Volunteers must meet the core requirements based on the research purpose. For instance, if the purpose of study is to obtain the safety data regarding a research drug being tested on Chinese subjects, the core criteria of volunteers is certainly the ethnicity.

Exclusion Criteria:

It refers to certain conditions that volunteers should not be having, and so will be excluded from the study. The criteria is established based on the study purpose, aiming at volunteer protection, and to eliminate any factors that may interfere with the research data or process. For instance, if a research drug may affect the eye function, even if a volunteer meets all the inclusion criteria, they may still be excluded from participating in the study if they have undergone corrective eye surgery.